Anticoagulant Agents for Atrial Fibrillation in Cancer Patients
In a recent article in the journal, Patell et al1 found CHADS2 (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, prior stroke/transient ischemic attack/thromboembolism) and CHA2DS2VASC (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, prior stroke/transient ischemic attack/thromboembolism, vascular disease, age 65-74, sex category [i.e., female]) to predict risk of ischemic stroke in cancer patients with baseline atrial fibrillation (AF). Although only 36% of patients received anticoagulant therapy, the risk of stroke generally appeared to be lower than in cancer-free individuals.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Mireia Santos-Gomez, Elisa Orna Source Type: research
More News: Atrial Fibrillation | Cancer | Cancer & Oncology | Cardiology | Congestive Heart Failure | Diabetes | Diabetes Mellitus | Endocrinology | Heart | Heart Failure | Hypertension | Ischemic Stroke | Stroke | Thrombosis